Nuveen
LYEL icon

Nuveen’s Lyell Immunopharma LYEL Stock Holding History

Nuveen’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$177K Buy
+12,595
New +$228K ﹤0.01% 3659
2025
Q2 		– Sell
-32,059
Closed -$345K – 3345
2025
Q1 		$345K Hold
32,059
– – ﹤0.01% 3006
2024
Q4 		$410K Sell
32,059
-10,765
-25% -$213K ﹤0.01% 3045
2024
Q3 		$1.18M Buy
42,824
+661
+2% +$19.4K ﹤0.01% 2678
2024
Q2 		$1.22M Sell
42,163
-440
-1% -$20.9K ﹤0.01% 2630
2024
Q1 		$1.9M Buy
42,603
+6,128
+17% +$262K ﹤0.01% 2429
2023
Q4 		$1.42M Sell
36,475
-88
-0.2% -$3.17K ﹤0.01% 2574
2023
Q3 		$1.07M Buy
36,563
+7,005
+24% +$333K ﹤0.01% 2546
2023
Q2 		$1.88M Buy
29,558
+7,178
+32% +$397K ﹤0.01% 2378
2023
Q1 		$1.06M Sell
22,380
-2,471
-10% -$132K ﹤0.01% 2587
2022
Q4 		$1.73M Sell
24,851
-4,334
-15% -$431K ﹤0.01% 2454
2022
Q3 		$4.28M Sell
29,185
-707
-2% -$95.7K ﹤0.01% 1993
2022
Q2 		$3.9M Buy
29,892
+2,202
+8% +$225K ﹤0.01% 2111
2022
Q1 		$2.83M Buy
27,690
+24,046
+660% +$2.91M ﹤0.01% 2353
2021
Q4 		$662K Buy
3,644
+1,354
+59% +$302K ﹤0.01% 2996
2021
Q3 		$678K Buy
+2,290
New +$686K ﹤0.01% 3111

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Nuveen's LYEL Position: Q2 2026 in Review

Nuveen opened a new position in Lyell Immunopharma (LYEL) in Q2 2026: 12,595 shares worth $177K. The stake represents ﹤0.01% of the portfolio and ranks #3659 among its holdings. This is a return to the name: Nuveen previously reported a position in LYEL as recently as Q1 2025.

Nuveen first reported a position in LYEL in Q3 2021 and has held it in 16 quarters since. The position peaked at $4.28M in Q3 2022. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • Nuveen held 12,595 shares of Lyell Immunopharma worth $177K as of Q2 2026.
  • Lyell Immunopharma was a new Nuveen position in Q2 2026.
  • Lyell Immunopharma made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3659 holding.
  • Nuveen first reported a position in Lyell Immunopharma in Q3 2021 and has held it in 16 quarters since.
  • Nuveen's Lyell Immunopharma position peaked at $4.28M in Q3 2022.
  • 87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.